
Please try another search
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Edward T. Mathers | 65 | 2012 | Independent Director |
Timothy K. Lu | 44 | - | Co-Founder & Member of Scientific Advisory Board |
Cammie Lesser | - | - | Member of Scientific Advisory Board |
Peter Barrett | 72 | 2014 | Independent Chairman of the Board |
James J. Collins | 58 | - | Co-Founder & Member of Scientific Advisory Board |
Paul Francis Miller | 64 | 2014 | Member Scientific Advisory Board |
Richard P. Shea | 73 | 2017 | Independent Director |
Kristala Lanett Jones Prather | - | - | Member of Scientific Advisory Board |
James P. Flynn | 43 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review